Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-granted-fda-priority-review-adjuvant-treatment-stage-iii-braf-v600-mutation-positive-melanomaPriority Review designation based on Phase III study showing 53% reduction in risk of recurrence or death with Tafinlar + Mekinist, as compared to placebo[1] Improvements observed in key…
- https://www.novartis.com/news/media-releases/novartis-announces-oncology-head-retireBasel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of…
- https://www.novartis.com/news/media-releases/novartis-gibt-rucktritt-des-onkologie-chefs-bekanntBasel, 15. Dezember 2017 - Novartis gibt bekannt, dass sich Bruno Strigini, CEO Novartis Onkologie, entschieden hat, die Firma aus persönlichen Gründen zu verlassen und sich aus der Industrie…
- https://www.novartis.com/news/media-releases/novartis-drug-crizanlizumab-shown-prolong-time-patients-first-sickle-cell-pain-crisis-subgroup-analysis-sustain-studyInvestigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN…
- https://www.novartis.com/news/media-releases/primary-analysis-results-from-novartis-pivotal-juliet-trial-show-kymriahtm-tisagenlecleucel-sustained-complete-responses-six-months-adults-rr-dlbcl-difficult-treat-cancerAt six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4…
- https://www.novartis.com/news/media-releases/sandoz-announces-new-phase-i-data-showing-proposed-biosimilar-pegfilgrastim-matches-reference-medicinePhase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a…
- https://www.novartis.com/news/media-releases/novartis-tender-offer-advanced-accelerator-applications-commencesBasel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of…
- https://www.novartis.com/news/media-releases/kisqali-first-and-only-cdk46-inhibitor-show-superior-efficacy-vs-oral-endocrine-therapy-1l-treatment-randomized-phase-iii-trial-premenopausal-women-hrher2-advanced-breast-cancerKisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and…
- https://www.novartis.com/news/media-releases/novartis-cosentyx-first-biologic-show-long-term-efficacy-nail-and-palmoplantar-psoriasis-which-can-impact-90-psoriasis-patientsUnique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data…
- https://www.novartis.com/news/media-releases/novartis-steigert-im-dritten-quartal-umsatz-und-gewinn-allen-divisionenDer Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen, +…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 263
- › Next page